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dialysis program are diabetics. Most are type II diaMethods. One hundred and thirty-seven type II betics [1] . Compared with other patients on chronic diabetics receiving regular haemodialysis in a single dialysis, diabetics experience increased morbidity [2] [3] university hospital were enrolled. The patients were and decreased survival [4 ] . Besides diabetic nephroclassified as either good or poor glycaemic control pathy, the diabetic patients, both insulin-dependent group according to their glycaemic control within 6 and non-insulin-dependent, are vulnerable to many months before starting haemodialysis. Serum albumin, diabetic late complications, such as retinopathy, neurohaematocrit, cholesterol, triglyceride, residual renal pathy, and cardiovascular diseases which cause serious function, diabetic complications, and patient survival morbidity [5] [6] [7] . The excess mortality of diabetic endwere analysed in both groups.
stage renal disease patients is attributed to these Results. There was no significant difference in age, co-morbidities [4 ] . The results from the Diabetes gender, predialysis albumin level, cholesterol level, Control and Complications Trial (DCCT ) revealed triglyceride level, and residual renal function between that hyperglyacemia is the single main cause of these the two groups. The 1-year (94.5% vs 80.0%), 3-year complications. Improved glycaemic control as a result ( 82.9% vs 58.1%), and 5-year (75.8% vs 21.8%) cumu-of intensive insulin treatment has the potential to lative survival rates were lower in the poor glycaemic reduce the incidence and the progression of complicacontrol group than in the good glycaemic control tions in type I diabetics [8] . With this intensive insulin group (P<0.001). The poor glycaemic control group therapy, however, some of the diabetic patients still also had more cardiovascular morbidity during the progress into end-stage renal disease which requires period of dialysis (P<0.001). The increase in cardio-long-term renal replacement therapy. As diabetic vascular complications also accounted for the increased nephropathy progresses, leading to end-stage renal mortality during the course of haemodialysis. disease, it is still unknown whether the intensive glycaConclusions. We conclude that poor glycaemic control emic control before starting haemodialysis will decrease before starting dialysis is a strong predictor of cardio-the diabetic co-morbidity and subsequently improve vascular morbidity and survival for type II diabetics the long-term outcome of chronic haemodialysis in on haemodialysis. These results imply that better glyca-these diabetic patients, specifically, type II diabetics emic control before dialysis might be important in which account for >90% of our chronic dialysis improving the long-term prognosis in type II diabetics patients. To our knowledge, there has been no study on haemodialysis.
focusing on the influence of glycaemic control status before dialysis therapy on the clinical outcomes of type II diabetic ESRD patients, which are the major population of diabetic patients in our dialysis program.
on a personal computer using StatView 4.1 with Survival and the clinical outcomes for type II diabetic patients Tool ( Abacus Concept Inc., Berkeley, CA, USA).
on maintenance haemodialysis. In addition, other parameters before starting long-term dialysis including serum albumin, serum cholesterol, residual renal func-
Results
tion, and mode of glycaemic control were examined for any impact on clinical outcome. The study of these issues is very important, since they imply that better There were no significant differences in the mean age entering dialysis program and genders between group glycaemic control before starting long-term dialysis is paramountly important for long-term prognosis in this G and group P ( Table 1 ). The haematocrit, serum albumin, cholesterol, triglyceride, and residual renal specific diabetic population. function before starting haemodialysis showed no significant difference between the two groups ( Table 2 ). There were no significant differences between incidence
Methods
of hypertension, i.e. >160/95 mmHg and requiring antihypertensive medications (87% vs 89%, group G We conducted a retrospective analysis of diabetic patients in vs group P), and ischaemic heart disease requiring a single dialysis unit of a medical center (Chang-Gung hospitalization ( 17% vs 16%) between groups G and Memorial Hospital, Taipei, Taiwan). Diabetes was diagnosed P before starting haemodialysis. On the other hand, according to the WHO criteria [9] . From January 1985 to there was significantly more diabetic proliferative preretinal or vitreous haemorrhage, or fibrous tissue Diabetes was the cause of ESRD in all patients. Blood glucose and glycosylated haemoglobin (HbA1C ) were meas-proliferation [13 ] in group P (44% vs 76%, P<0.001). ured to assess the glycaemic control. A glucose oxidase These observations suggested that the incidence of method was used for blood glucose measurement [10 ] . cardiac co-morbidity showed no difference between the HbA1C was measured by affinity chromatography. Blood two groups, but there was significantly more incidences glucose level within 60-200 mg/dl and HbA1C levels <10% of microvascular complication, as presented by the were considered as indicatives of satisfactory glycaemic con-diabetic proliferative retinopathy, in group P on
entering the long-term haemodialysis programs.
Patients were separated into two groups according to the When the patients entered the maintenance haemostatus of glycaemic control within 6 months before starting dialysis programs, there was a significantly higher maintenance haemodialysis. In the good glycaemic control incidence of congestive heart failure, myocardial infarcgroup (group G), >50% of blood glucose determinations were within 60-200 mg/dl and HbA1C within 5-10%. In the tion, diabetic proliferative retinopathy, and gastrointegroup with poor glycaemic control (group P), <50% of stinal bleeding for patients in group P (Table 3 ) . blood glucose determinations were within 60-200 mg/dl or However, no significant difference was observed in the HbA1C >10%. In addition to glycaemic control status, incidence of hypertension, cerebrovascular accident, serum albumin, cholesterol levels, residual renal function hyperosmolar hyperglycaemic nonketotic coma, dia-(estimated by creatinine clearance study), and the modes of betic ketoacidosis, and diabetic foot requiring glycaemic control before the start of haemodialysis were also amputation between these two groups. In spite of good evaluated to see if there was any impact of these factors on glycaemic control, there was no significantly higher the clinical outcome of these diabetic patients.
incidence of hypoglycaemic episodes requiring admisComplications before and during the dialysis period, sion in group G. The increased cardiac and microvascuincluding diabetic proliferative retinopathy, hypertension, myocardial infarction, congestive heart failure, cerebro-lar co-morbidity after starting haemodialysis in vascular accident, hyperosmolar hyperglycaemic nonketotic group P suggested that some of the glycaemic-related coma (HHNK ), diabetic ketoacidosis (DKA), hypoglycae-cardiovascular complications developed after the onset mia, gastrointestinal bleeding, and diabetic foot requiring of ESRD. amputation, as well as causes of death were reviewed.
The patients in group G had significantly higher Congestive heart failure was diagnosed if patients met criteria 1-year (94.5% vs 80.0%), 3-year (82.9% vs 58.1%), and for class III or IV of the New York American Heart 5-year ( 75.8% vs 21.8%) survival rates compared to Association classification. those in group P (P<0.0001) (Figure 1 ). To test the predicting power of serum albumin, serum cholesterol, and residual renal function before starting haemodiaStatistical analysis lysis, we also divided the patients into groups according Continuous variables were expressed as mean±standard to these parameters. No significant difference in cumudeviation. For normally distributed continuous variables, lative survival rates was noted between the patients two-tailed Student's unpaired t-test was used to test for with albumin Á3.0 mg/dl, cholesterol Á200 mg/dl, differences between means. Differences in categorical vari-and creatinine clearance Á5 ml/min ( Figure 2) . We ables were examined by the x2-test with Yate's correction. also examined the impact of modes of glycaemic con- 
Discussion
[ Exp(coef )=1.003, P=0.4618] had no significant impact on the patients survival. The four variables were further examined by multivariate analysis: only In the DCCT study [8] , insulin-dependent diabetic patients with intensive insulin treatment tended to have glycaemic control and age still had significant impact on patient survival (Table 4 ) . a substantially less risk of development or progression of diabetic retinopathy, microalbuminuria, and neuroCauses of death were reviewed in these patients ( Table 5 ). Cardiovascular diseases accounted for 50% pathy. The most impressive results after improved metabolic control were a decrease in the progression of the deaths in the group P. This was 2-fold higher than in group G. Infection is another major cause of of retinopathy and a reduction in the risk of sight-threatening proliferative retinopathy. Regarding death. Cardiovascular diseases accounted for the major part of the increased mortality in the patients in nephropathy, the results demonstrated a retardation of progression to clinical nephropathy in patients with group P. The higher incidence of infection-related mortality compared to that of the large registry data intensive glycaemic control in type I diabetics after a 3-year observation period. Therefore, intensive glyca- [4 ] was also noted. These results might be due to the generalized lower incidence of cardiovascular disease, emic control appears to have a great impact on the Fig. 2 . No significant difference in cumulative survival rates was noted between the patients with albumin Á3.0 mg/dl, cholesterol Á200 mg/dl, creatinine clearance Á5 ml/min, and with different diabetic controlling methods.
progression of diabetic renal failure in type I diabetic However, some of the diabetic patients inevitably progressed to ESRD and had to receive chronic dialysis patients. Recently, the salutary effect of good glycaemic control was also summarized in a review of progression therapy. These results raise a further question. Whether better glycaemic control during the progression of of diabetic nephropathy in type II diabetes [14] . vascular co-morbidity or not, our results simply demonstrate that poor predialysis glycaemic control itself could faithfully predict the long-term mortality of type II diabetic haemodialysis patients. Taken together, renal failure, having salutary effects on prevention of progression, would also have any impact on long-term our results indirectly suggest that poor glycaemic control might induce diabetic microvascular complications clinical outcome of type II diabetic nephropathy patients, who finally go into chronic dialysis program which commenced before the development of diabetic ESRD. The subsequent cardiovascular co-morbidity and account for >30% of long-term haemodialysis patients.
was responsible for the shortened survival in type II diabetic patients on chronic dialysis. In our observations, we clearly demonstrated that poor glycaemic control before entering chronic dialysis Hyperglycaemia is the primary metabolic abnormality responsible for the development of irreversible program in type II diabetic patients was a strong predictor of cardiovascular morbidity and long-term tissue damage in chronic diabetes. Among the mechanisms by which hyperglycaemia may lead to tissue dialysis survival. The relationship between glycaemic control and patient survival observed in our study damage, the role of nonenzymatic glycosylation of long-lived protein had recently attracted much could be interpreted in three ways: (i) poor glycaemic control directly results in late complications which attention [17 ] . Advanced glycosylation end-products (AGEs) form spontaneously from glucose-derived precede nephropathy and hence shorten survival even after maintenance dialysis; (ii) some risk factors, i.e. Amadori products and accumulate on long-lived tissue proteins. AGEs covalently trap extravasated serum malnutrition, result in both poor glycaemic control and late complications; (iii) the co-morbidity condi-proteins to the extracellular matrix, and thus may contribute to capillary closure in the retina and glomertions do not satisfy the glycaemic control. In our observations, there is no significant difference in pre-ulus and to arterial narrowing in the coronary, cerebral, renal, and peripheral circulation [18] [19] . The elevation dialysis serum albumin and cholesterol, which represents the generalized nutritional status, between good of AGEs in blood and tissue appear very early in the course of chronic diabetes. A significant increase in and poor glycaemic control groups in this specific population of diabetic patients who were invariably AGEs was found in urine in the pre-microalbuminuria phase of nephropathy [20 ] . These results suggest that very sick and malnourished at the time of entering long-term dialysis. Moreover, there was no difference irreversible end-organ damage might start far before the development of ESRD. Prolonged poor glycaemic in survival rates between patients with low and high predialysis serum albumin in these specific groups of control accelerated these spontaneous nonenzymatic reactions and caused accumulation of AGEs which patients. These results were contrary to the previous studies [15] [16] , which indicated that serum albumin might be responsible for cardiovascular co-morbidity conditions in our poor glycaemic control patients. during dialysis was an independent strong predictor of long-term survival, most of whom were non-diabetic Previous studies indicate that in type II diabetic ESRD patients, long-term survivors (surviving >24 months) elderly patients. The patient population difference might explain the different results observed. Our results showed a better metabolic control of diabetes [21] and good glycaemic control during the first 6 months of might also imply that nutritional factors could be corrected after starting chronic dialysis and predialysis dialysis predicted long-term survival for type II diabetics [22] . Our results suggest that glycaemic control glycaemic control was not related to serum albumin in type II diabetic patients. We found no difference of affects long-term outcome in type II diabetic patients even before starting dialysis. The question remains the prevalence of hypertension and ischaemic heart disease before dialysis between these two groups, but open whether improved glycaemic control after starting chronic dialysis would reverse this predicting power. there was much more diabetic proliferative retinopathy in the poor glycaemic control group. This suggests that
In conclusion, we demonstrated that glycaemic control before starting dialysis is a predictor of survival the observed poor glycaemic control might not be a consequence of pre-existing hypertension and for type II diabetics on haemodialysis. Patients with poor predialysis glycaemic control were associated with ischaemic heart disease. The increased incidence of pre-existing microvascular complications, indicated by increased cardiovascular morbidity and shortened survival after haemodialysis. These results imply that diabetic proliferative retinopathy, in the poor glycaemic control group might imply that irreversible micro-better glycaemic control before dialysis is important in
